JP2021184734A5 - - Google Patents

Download PDF

Info

Publication number
JP2021184734A5
JP2021184734A5 JP2021130440A JP2021130440A JP2021184734A5 JP 2021184734 A5 JP2021184734 A5 JP 2021184734A5 JP 2021130440 A JP2021130440 A JP 2021130440A JP 2021130440 A JP2021130440 A JP 2021130440A JP 2021184734 A5 JP2021184734 A5 JP 2021184734A5
Authority
JP
Japan
Prior art keywords
nucleic acid
acid molecule
cell
itr2
itr1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021130440A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021184734A (ja
JP7316326B2 (ja
Filing date
Publication date
Priority claimed from JP2017559315A external-priority patent/JP6929230B2/ja
Application filed filed Critical
Publication of JP2021184734A publication Critical patent/JP2021184734A/ja
Publication of JP2021184734A5 publication Critical patent/JP2021184734A5/ja
Priority to JP2023115773A priority Critical patent/JP2023138527A/ja
Application granted granted Critical
Publication of JP7316326B2 publication Critical patent/JP7316326B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021130440A 2015-05-14 2021-08-10 スペーサーを含む核酸分子およびその使用の方法 Active JP7316326B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023115773A JP2023138527A (ja) 2015-05-14 2023-07-14 スペーサーを含む核酸分子およびその使用の方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562161505P 2015-05-14 2015-05-14
US62/161,505 2015-05-14
JP2017559315A JP6929230B2 (ja) 2015-05-14 2016-05-13 スペーサーを含む核酸分子およびその使用の方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2017559315A Division JP6929230B2 (ja) 2015-05-14 2016-05-13 スペーサーを含む核酸分子およびその使用の方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023115773A Division JP2023138527A (ja) 2015-05-14 2023-07-14 スペーサーを含む核酸分子およびその使用の方法

Publications (3)

Publication Number Publication Date
JP2021184734A JP2021184734A (ja) 2021-12-09
JP2021184734A5 true JP2021184734A5 (enExample) 2022-01-18
JP7316326B2 JP7316326B2 (ja) 2023-07-27

Family

ID=57249066

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017559315A Active JP6929230B2 (ja) 2015-05-14 2016-05-13 スペーサーを含む核酸分子およびその使用の方法
JP2021130440A Active JP7316326B2 (ja) 2015-05-14 2021-08-10 スペーサーを含む核酸分子およびその使用の方法
JP2023115773A Pending JP2023138527A (ja) 2015-05-14 2023-07-14 スペーサーを含む核酸分子およびその使用の方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2017559315A Active JP6929230B2 (ja) 2015-05-14 2016-05-13 スペーサーを含む核酸分子およびその使用の方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023115773A Pending JP2023138527A (ja) 2015-05-14 2023-07-14 スペーサーを含む核酸分子およびその使用の方法

Country Status (5)

Country Link
US (2) US11103597B2 (enExample)
EP (1) EP3294309A4 (enExample)
JP (3) JP6929230B2 (enExample)
AU (3) AU2016260401B2 (enExample)
WO (1) WO2016183422A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016260401B2 (en) 2015-05-14 2022-05-19 St. Jude Children's Research Hospital, Inc. Nucleic acid molecules containing spacers and methods of use thereof
EP3361869B1 (en) * 2015-10-14 2025-12-03 Audentes Therapeutics, Inc. Nucleic acid molecules containing spacers and methods of use thereof
WO2018191622A1 (en) * 2017-04-14 2018-10-18 Rhode Island Hospital Vegf gene therapy for tendon and ligament injuries
KR102780287B1 (ko) 2017-08-09 2025-03-14 바이오버라티브 테라퓨틱스 인크. 핵산 분자 및 이의 용도
CA3092088A1 (en) * 2018-03-15 2019-09-19 Igtx, Llc Synthetic dna vectors and methods of use
BR112021002017A2 (pt) 2018-08-09 2021-05-11 Bioverativ Therapeutics Inc. moléculas de ácido nucleico e usos das mesmas para terapia genética não viral
CA3112883A1 (en) 2018-10-25 2020-04-30 Baxalta Incorporated Aav triple-plasmid system
CA3151464A1 (en) 2019-09-18 2021-03-25 Bruce C. SCHNEPP Synthetic dna vectors and methods of use
CN115197967B (zh) * 2021-04-08 2023-09-15 广州派真生物技术有限公司 制备重组腺相关病毒的辅助质粒及其应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5478745A (en) 1992-12-04 1995-12-26 University Of Pittsburgh Recombinant viral vector system
JP2001500014A (ja) * 1996-09-06 2001-01-09 トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 組換えアデノ随伴ウイルスの生産のためにcre―loxを用いる方法
US6346415B1 (en) * 1997-10-21 2002-02-12 Targeted Genetics Corporation Transcriptionally-activated AAV inverted terminal repeats (ITRS) for use with recombinant AAV vectors
WO2001036623A2 (en) * 1999-11-05 2001-05-25 Avigen, Inc. Ecdysone-inducible adeno-associated virus expression vectors
US20020182595A1 (en) 2001-04-27 2002-12-05 Weitzman Matthew D. Method of identifying cellular regulators of adeno-associated virus (AAV)
WO2002097056A2 (en) 2001-05-31 2002-12-05 The Rockefeller University Method for generating replication defective viral vectors that are helper free
US7419817B2 (en) 2002-05-17 2008-09-02 The United States Of America As Represented By The Secretary Department Of Health And Human Services, Nih. Scalable purification of AAV2, AAV4 or AAV5 using ion-exchange chromatography
CA2500397A1 (en) 2002-09-26 2004-04-08 Greenville Hospital System Aav itr-mediated modulation
EP1804839B1 (en) * 2004-09-22 2012-03-14 St. Jude Children's Research Hospital Improved expression of factor ix in gene therapy vectors
ES2683695T3 (es) 2010-01-12 2018-09-27 The University Of North Carolina At Chapel Hill Repeticiones terminales invertidas restrictivas para vectores virales
US9249425B2 (en) * 2011-05-16 2016-02-02 The Trustees Of The University Of Pennslyvania Proviral plasmids and production of recombinant adeno-associated virus
TWI775096B (zh) * 2012-05-15 2022-08-21 澳大利亞商艾佛蘭屈澳洲私營有限公司 使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd)
US9124527B2 (en) * 2012-08-29 2015-09-01 International Business Machines Corporation Sliced routing table management
EP2911687B1 (en) 2012-10-26 2019-02-13 Vrije Universiteit Brussel Vector for liver-directed gene therapy of hemophilia and methods and use thereof
RU2015139732A (ru) 2013-03-15 2017-04-24 ЛУМЕНА ФАРМАСЬЮТИКАЛС ЭлЭлСи Ингибиторы рециркуляции желчных кислот для лечения пищевода барретта и гастроэзофагеальной рефлюксной болезни
CA2904156C (en) * 2013-03-15 2023-01-10 The Children's Hospital Of Philadelphia Vectors comprising stuffer/filler polynucleotide sequences and methods of use
CA2919103C (en) * 2013-07-22 2023-10-10 The Children's Hospital Of Philadelphia Variant aav and compositions, methods and uses for gene transfer to cells, organs and tissues
CN107427557B (zh) * 2014-08-13 2022-01-04 费城儿童医院 用于包装和表达变体因子viii以治疗血友病的改良表达组件
AU2016260401B2 (en) 2015-05-14 2022-05-19 St. Jude Children's Research Hospital, Inc. Nucleic acid molecules containing spacers and methods of use thereof

Similar Documents

Publication Publication Date Title
JP2021184734A5 (enExample)
JP2020533963A5 (enExample)
Whitehouse et al. Antagonistic forces that position nucleosomes in vivo
JP2018515102A5 (enExample)
HRP20241180T1 (hr) Modificirani faktor ix, te pripravci, postupci i upotreba za prijenos gena u stanice, organe i tkiva
Suzuki et al. Rice MYB protein OSMYB5 specifically binds to the AACA motif conserved among promoters of genes for storage protein glutelin
JP6929230B2 (ja) スペーサーを含む核酸分子およびその使用の方法
Richardson et al. Requirement for either early region 1a or early region 1b adenovirus gene products in the helper effect for adeno-associated virus
Suzuki et al. Preferable sites and orientations of transgene inserted in the adenovirus vector genome: The E3 site may be unfavorable for transgene position
WO2020142714A1 (en) Aav expression cassette and aav vectors comprising the same
CN113234702A (zh) 一种Lt1Cas13d蛋白及基因编辑系统
CN116286724A (zh) 凝集素类受体蛋白TaLecRLK2及其编码基因与应用
Pondel et al. The LCR-like α-globin positive regulatory element functions as an enhancer in transiently transfected cells during erythroid differentiation
CN102234647B (zh) 一个水稻逆境诱导启动子kt619p的鉴定和应用
Buvoli et al. Potential limitations of transcription terminators used as transgene insulators in adenoviral vectors
Haun et al. Characterization of the human ADP-ribosylation factor 3 promoter. Transcriptional regulation of a TATA-less promoter.
Strauss et al. The MDR1 downstream promoter contains sequence-specific binding sites for wild-type p53
Kucharova et al. Design and optimization of short DNA sequences that can be used as 5′ fusion partners for high-level expression of heterologous genes in Escherichia coli
CN102725408B (zh) 猪肌抑素基因启动子及其应用
Qin et al. The 3′-end of the human β-actin gene enhances activity of the β-actin expression vector system: construction of improved vectors
CN111926019B (zh) 与Pol II和Pol III亲和力增强的H1启动子
CN116981776A (zh) 使用合成启动子控制多基因表达
Clément et al. Construction and production of oncotropic vectors, derived from MVM (p), that share reduced sequence homology with helper plasmids
Anderson et al. A gene-sized DNA molecule encoding heat-shock protein 70 in Oxytricha nova
WO2003006659B1 (en) Plant transcriptional repressor, proteic nuclear factors binding thereto, and uses thereof